CAS · 49562-28-9
Product Overview
Fenofibrate is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Grade: | EP8.0 & BP2013 |
|---|---|
| Character: | White or almost white, crystalline powder |
| Assay (on anhydrous basis): | 98%~102% |
| Identification: | Should comply with the IR spectrum |
| Appearance of solution: | Clear and not more colored than BY6 |
| Melting range: | 79～82℃ |
| Acidity: | 0.2 ml max |
| Related substances - Impurity A: | 0.1% max |
| Related substances - Impurity B: | 0.1% max |
| Related substances - Impurity G: | 0.2% max |
| Related substances - Unspecified impurities: | 0.1% max |
| Related substances - Total impurity: | 0.5% max |
| Halides (as chlorides): | 100 ppm max |
| Sulfates: | 100 ppm max |
| Heavy metals: | 20 ppm max |
| Sulphated ash: | 0.1% max |
| Loss on drying: | 0.5% max |
| Acetone: | 5000 ppm max |
| 2-Propanol: | 5000 ppm max |
| Toluene: | 890 ppm max |
| Butyl acetate: | 5000 ppm max |
Applications
Fenofibrate is a lipid-modifying pharmaceutical compound widely used in the management of hyperlipidemia and hypertriglyceridemia. As a fibric acid derivative, it functions as a prodrug that is converted in vivo to fenofibric acid, its active metabolite. Fenofibric acid activates peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor that regulates lipid metabolism. This activation leads to increased oxidation of fatty acids, reduced triglyceride levels, enhanced high-density lipoprotein (HDL) cholesterol, and decreased low-density lipoprotein (LDL) cholesterol concentrations. Clinically, Fenofibrate is prescribed either as monotherapy or in combination with statins to reduce cardiovascular risk associated with dyslipidemia. Beyond therapeutic applications, it is used in pharmacological research to study lipid metabolism pathways, gene regulation mechanisms, and metabolic disorders. Its properties also make it useful as a reference compound in quality control and drug development laboratories.
Benefits
Fenofibrate offers multiple clinical and biochemical benefits due to its targeted action on lipid metabolism. It effectively lowers triglyceride levels by promoting lipolysis and eliminating very-low-density lipoproteins (VLDL) from plasma. Simultaneously, it raises HDL cholesterol levels, contributing to improved lipid balance and cardiovascular protection. Fenofibrate's PPARα activation not only modulates lipid transport but also exerts anti-inflammatory and antioxidant effects, which may further reduce the risk of atherosclerosis and endothelial dysfunction. It demonstrates good oral bioavailability and tolerability, making it suitable for long-term treatment in patients with metabolic syndromes. Additionally, its broad compatibility with combination therapies enhances its utility in managing complex dyslipidemic profiles. From a pharmaceutical standpoint, Fenofibrate's stability and well-characterized pharmacokinetic behavior make it a reliable compound for formulation and research purposes.
Conclusion
Fenofibrate is a well-established lipid-regulating drug that plays a key role in the prevention and management of cardiovascular and metabolic diseases. By improving lipid profiles through PPARα activation and offering added anti-inflammatory benefits, it helps reduce the risk of coronary artery disease and related complications. Its proven efficacy, safety, and versatility have made it a cornerstone therapy in the treatment of dyslipidemia, while its use in research continues to advance understanding of lipid metabolism and cardiovascular health.
Previous
Next